WNT signalling pathways as therapeutic targets in cancer

By Jamie N Anastas, R. Moon. Nature Reviews. Cancer, 2012

1,926 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/f7b073138f42af9d86668f4aafaa23f9b5dd8d76

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Young Chul Kim
2. K. Guan
3. Fa-Xing Yu
4. Eléonore Beurel
5. Toshiro Moroishi
6. Z. Meng
7. S. Grieco
8. H. Park

In Oncology

1. K. Guan
2. Z. Meng
3. Toshiro Moroishi
4. Philipp Kaldis
5. Fa-Xing Yu

Citations in the corpus

• Exosomes in Cancer Development, Metastasis and Drug Resistance: A Comprehensive Review (2013, neutral): “Targeting of Wnt signaling for cancer therapy has been intensely investigated [184].”
• Cdks, cyclins and CKIs: roles beyond cell cycle regulation (2013, background): “Therefore, suppressing the Wnt pathway became an attractive route for therapeutic intervention (Anastas and Moon, 2013).”
• INTERNATIONAL UNION OF BASIC AND CLINICAL PHARMACOLOGY REVIEW WNT/Frizzled signalling: receptor-ligand selectivity with focus on FZD-G protein signalling and its physiological relevance: IUPHAR Review 3 (2014, neutral): “1204 British Journal of Pharmacology (2014) 171 1195–1209 Agonists and antagonists targeting FZD as well as positive and negative allosteric modulators would be of great value and could serve as pharmacophores for the development of new drugs (Chien and Moon, 2007; Anastas and Moon, 2013).”
• Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma (2013, background): “Aberrant activation of Wnt/β-catenin signaling has been implicated in tumorigenesis, and many downstream components of the Wnt pathway are mutated in cancers (6).”
• Alternative Wnt Signaling Activates YAP/TAZ (2015, background): “In addition, Wnt5a and ROR1/2 are potent inducers of tumor metastasis, and their expression correlates with decreased patient survival in various human malignancies (Anastas and Moon, 2013).”
• Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases (2014, background): “The variable role of GSK3 in different cancers also may be related to the role of β-catenin, which can be activated by GSK3 inhibitors (Polakis, 2007; Anastas and Moon, 2012).”